0.35Open0.35Pre Close0 Volume361 Open Interest2.50Strike Price0.00Turnover0.00%IV-4.37%PremiumJul 19, 2024Expiry Date0.44Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.15Leverage Ratio--Theta--Rho--Eff Leverage--Vega
LAVA Therapeutics Stock Discussion
LAVA Therapeutics N.V., a leader in the biotechnology sector, has recently announced a significant clinical development milestone achieved by Pfizer for the drug PF-08046052. This milestone has prompted the first payment of $7 million to LAVA, marking a notable event in the field of immuno-oncology. $LAVA Therapeutics(LVTX.US)$
https://stockregion.app/p/biotech-leader-announces-7m-milestone
No comment yet